We don’t follow footsteps.
We create the path.

News & events

59th ASH Annual Meeting
Spark Therapeutics presents updated hemophilia A and B data at the 2017 American Society of Hematology Annual Meeting

Read More read more

Hemophilia B data published in NEJM
The New England Journal of Medicine published data from Spark’s Phase 1/2 study of investigational SPK-9001

Read More read more

New Posting on Health Affairs Magazine Blog: 
Advancing Gene Therapies Through Value-Based Payment Reform

Read More read more

50 Companies to Watch in 2018
Bloomberg names Spark Therapeutics to its annual list of companies to watch in the year ahead

Read More read more

Get our news alerts delivered straight to your inbox

Subscribe Now

We don’t follow footsteps. We create the path.

Our mission at Spark Therapeutics is to challenge the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable—until now. We have built a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and commercial operations. Find out more about how we strive to turn genes into medicines for patients with inherited diseases, including inherited retinal diseases (IRDs), liver-mediated diseases such as hemophilia, and neurodegenerative diseases.

Learn More